• Consensus Rating: Buy
  • Consensus Price Target: $280.17
  • Forecasted Upside: 2.99 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$272.04
▲ +1.74 (0.64%)

This chart shows the closing price for IQV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IQVIA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IQV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IQV

Analyst Price Target is $280.17
▲ +2.99% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for IQVIA in the last 3 months. The average price target is $280.17, with a high forecast of $320.00 and a low forecast of $230.00. The average price target represents a 2.99% upside from the last price of $272.04.

This chart shows the closing price for IQV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 18 contributing investment analysts is to buy stock in IQVIA. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2021Piper SandlerBoost Price TargetNeutral$250.00 ➝ $261.00Medium
11/18/2021MizuhoBoost Price TargetBuy$282.00 ➝ $290.00Low
11/17/2021Jefferies Financial GroupBoost Price TargetBuy$300.00 ➝ $309.00Medium
11/17/2021CitigroupBoost Price TargetBuy$300.00 ➝ $320.00Medium
11/17/2021KeyCorpBoost Price TargetOverweight$270.00 ➝ $290.00Medium
11/17/2021UBS GroupBoost Price TargetPositive ➝ Buy$298.00 ➝ $310.00Medium
11/12/2021Evercore ISIReiterated RatingOutperformMedium
10/28/2021MizuhoBoost Price TargetBuy$270.00 ➝ $282.00Low
10/27/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$250.00 ➝ $282.00Low
10/25/2021BarclaysBoost Price TargetOverweight$285.00 ➝ $287.00Low
10/22/2021Stifel NicolausBoost Price TargetBuy$300.00 ➝ $304.00Low
10/22/2021Morgan StanleyBoost Price TargetOverweight$280.00 ➝ $290.00Medium
10/22/2021CitigroupBoost Price TargetBuy$280.00 ➝ $300.00Medium
10/15/2021KeyCorpBoost Price TargetOverweight$260.00 ➝ $270.00Low
9/10/2021ArgusBoost Price TargetBuy$260.00 ➝ $290.00Low
7/28/2021Morgan StanleyBoost Price TargetOverweight$260.00 ➝ $280.00Medium
7/28/2021MizuhoBoost Price TargetBuy$250.00 ➝ $270.00Low
7/28/2021Piper SandlerBoost Price TargetNeutral$204.00 ➝ $235.00Medium
7/28/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$244.00 ➝ $250.00Medium
7/28/2021CitigroupBoost Price TargetBuy$265.00 ➝ $280.00Medium
7/28/2021Robert W. BairdBoost Price TargetOutperform$273.00 ➝ $285.00Medium
7/20/2021Credit Suisse GroupBoost Price TargetOutperform$242.00 ➝ $265.00High
7/13/2021BarclaysBoost Price TargetOverweight$260.00 ➝ $285.00Low
5/14/2021KeyCorpBoost Price TargetOverweight$255.00 ➝ $260.00Medium
5/12/2021Canaccord GenuityBoost Price TargetBuy$220.00 ➝ $260.00Low
5/12/2021ArgusBoost Price TargetBuy$220.00 ➝ $260.00Low
4/26/2021TruistBoost Price Target$235.00 ➝ $260.00Low
4/26/2021Truist SecuritiesBoost Price TargetBuy$235.00 ➝ $260.00Low
4/26/2021Morgan StanleyBoost Price TargetOverweight$220.00 ➝ $260.00Low
4/26/2021BarclaysBoost Price TargetOverweight$235.00 ➝ $260.00Low
4/23/2021CitigroupBoost Price Target$225.00 ➝ $265.00Low
4/23/2021Jefferies Financial GroupBoost Price TargetBuy$259.00 ➝ $273.00Low
4/23/2021Robert W. BairdBoost Price TargetOutperform$238.00 ➝ $250.00Medium
4/23/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$200.00 ➝ $244.00Medium
4/23/2021MizuhoBoost Price TargetBuy$218.00 ➝ $250.00Medium
4/16/2021StephensUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00Medium
4/9/2021MizuhoBoost Price TargetBuy$210.00 ➝ $218.00Medium
3/15/2021KeyCorpUpgradeSector Weight ➝ Overweight$218.00High
3/8/2021BarclaysInitiated CoverageOverweight$220.00N/A
3/2/2021BarclaysInitiated CoverageOverweight$220.00Low
2/11/2021TruistBoost Price Target$197.00 ➝ $235.00Low
2/11/2021Wells Fargo & CompanyBoost Price TargetOverweight$205.00 ➝ $230.00Low
2/11/2021Robert W. BairdBoost Price TargetOutperform$208.00 ➝ $221.00Low
2/11/2021Morgan StanleyBoost Price TargetOverweight$205.00 ➝ $220.00Low
2/11/2021MizuhoBoost Price TargetBuy$200.00 ➝ $210.00Low
2/11/2021Piper SandlerBoost Price TargetNeutral$179.00 ➝ $204.00Low
12/18/2020MizuhoBoost Price TargetBuy$190.00 ➝ $200.00Medium
10/22/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$180.00 ➝ $196.00Low
10/21/2020UBS GroupBoost Price TargetBuy$204.00 ➝ $224.00Medium
10/21/2020Morgan StanleyBoost Price TargetOverweight$182.00 ➝ $195.00Medium
10/21/2020Piper SandlerBoost Price TargetNeutral$140.00 ➝ $179.00Medium
10/21/2020MizuhoBoost Price TargetBuy$180.00 ➝ $190.00Medium
7/23/2020Robert W. BairdBoost Price TargetOutperform$156.00 ➝ $180.00High
7/23/2020Morgan StanleyBoost Price TargetOverweight$158.00 ➝ $182.00High
7/23/2020Wells Fargo & CompanyBoost Price TargetOverweight$155.00 ➝ $185.00High
7/23/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$145.00 ➝ $180.00High
7/23/2020MizuhoBoost Price TargetBuy$153.00 ➝ $180.00High
7/23/2020CitigroupBoost Price TargetBuy$160.00 ➝ $200.00High
7/7/2020Bank of AmericaBoost Price TargetBuy$145.00 ➝ $156.00Medium
7/6/2020StephensInitiated CoverageEqual Weight$150.00Low
4/29/2020SunTrust BanksBoost Price TargetBuy$128.00 ➝ $172.00Medium
4/29/2020Piper SandlerBoost Price Target$115.00 ➝ $138.00High
4/29/2020Stifel NicolausBoost Price TargetBuy$159.00 ➝ $165.00High
4/29/2020Wells Fargo & CompanyBoost Price TargetOverweight$140.00 ➝ $150.00High
4/29/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$150.00 ➝ $145.00High
4/29/2020CitigroupBoost Price TargetTop Pick ➝ Buy$155.00 ➝ $160.00High
4/28/2020UBS GroupLower Price TargetBuy$200.00 ➝ $162.00High
4/9/2020CitigroupLower Price TargetBuy$195.00 ➝ $155.00Low
4/8/2020Piper SandlerLower Price Target$163.00 ➝ $115.00High
4/6/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$190.00 ➝ $150.00High
4/3/2020MizuhoLower Price TargetBuy$153.00 ➝ $120.00Medium
4/2/2020Credit Suisse GroupLower Price TargetOutperform$175.00 ➝ $157.00Low
3/31/2020Stifel NicolausLower Price TargetBuy$194.00 ➝ $159.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$190.00 ➝ $140.00Low
3/27/2020Morgan StanleyLower Price TargetOverweight$170.00 ➝ $158.00High
3/26/2020BarclaysLower Price TargetOverweight$192.00 ➝ $166.00Low
3/24/2020CfraLower Price TargetBuy$185.00 ➝ $110.00Medium
3/23/2020Jefferies Financial GroupLower Price TargetBuy$195.00 ➝ $127.00High
3/17/2020SunTrust BanksLower Price TargetBuy$184.00 ➝ $128.00Low
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$190.00High
2/13/2020Piper SandlerBoost Price Target$145.00 ➝ $163.00Medium
2/13/2020UBS GroupBoost Price TargetBuy$187.00 ➝ $200.00Low
2/13/2020Robert W. BairdBoost Price TargetOutperform$172.00 ➝ $181.00Low
2/13/2020JPMorgan Chase & Co.Boost Price TargetOverweight$180.00 ➝ $195.00Low
2/13/2020CitigroupBoost Price TargetBuy$185.00 ➝ $195.00Low
2/12/2020Stifel NicolausBoost Price TargetBuy$180.00 ➝ $194.00Low
2/12/2020CfraUpgradeHold ➝ Buy$148.00 ➝ $185.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$180.00Low
1/6/2020CitigroupInitiated CoverageBuy$185.00Medium
12/20/2019Credit Suisse GroupReiterated RatingBuy$170.00N/A
12/13/2019CfraUpgradeSell ➝ HoldLow
11/14/2019Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
7/25/2019Credit Suisse GroupBoost Price TargetOutperform$165.00 ➝ $170.00Low
7/25/2019Wells Fargo & CompanyBoost Price TargetOutperform$170.00 ➝ $178.00Low
7/25/2019JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $180.00Low
7/15/2019BarclaysSet Price TargetBuy$180.00Medium
6/27/2019SunTrust BanksBoost Price TargetBuy$155.00 ➝ $175.00Low
6/21/2019MizuhoUpgradeNeutral ➝ Buy$150.00 ➝ $175.00High
6/19/2019MizuhoBoost Price TargetNeutral ➝ Neutral$145.00 ➝ $150.00High
6/19/2019Credit Suisse GroupBoost Price TargetOutperform$159.00 ➝ $165.00High
6/19/2019Morgan StanleyBoost Price TargetOverweight$156.00 ➝ $170.00High
6/19/2019Stifel NicolausBoost Price TargetBuy$167.00 ➝ $178.00High
6/19/2019William BlairReiterated RatingOutperformHigh
5/28/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$160.00Low
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformLow
3/18/2019BarclaysBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $167.00Low
2/25/2019ArgusBoost Price TargetBuy ➝ Buy$140.00 ➝ $160.00Low
2/19/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$140.00 ➝ $160.00Low
2/15/2019BarclaysReiterated RatingBuy$155.00Low
2/15/2019UBS GroupSet Price TargetBuy$155.00 ➝ $170.00Low
2/15/2019Piper Jaffray CompaniesBoost Price TargetNeutral$148.00Low
1/18/2019Jefferies Financial GroupUpgradeHold ➝ Buy$136.00 ➝ $150.00High
1/11/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
12/3/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $145.00High
10/23/2018Royal Bank of CanadaBoost Price TargetOutperform$137.00Low
10/23/2018Piper Jaffray CompaniesBoost Price TargetNeutral$131.00High
10/23/2018BarclaysBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $140.00High
10/9/2018UBS GroupInitiated CoverageBuy ➝ BuyLow
10/2/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$143.00 ➝ $146.00Low
8/31/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$136.00 ➝ $145.00Low
8/23/2018ArgusSet Price TargetBuy$136.00Low
8/13/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$120.00 ➝ $140.00Low
8/6/2018MizuhoSet Price TargetHold$120.00Low
7/25/2018Piper Jaffray CompaniesReiterated RatingHold$97.00High
7/25/2018SunTrust BanksBoost Price TargetBuy$140.00High
7/25/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$127.00 ➝ $143.00High
7/25/2018JPMorgan Chase & Co.Boost Price TargetOverweight$135.00High
7/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$121.00 ➝ $130.00High
7/25/2018BarclaysReiterated RatingOverweight ➝ Overweight$120.00 ➝ $130.00High
7/25/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$128.00 ➝ $150.00High
7/25/2018Royal Bank of CanadaReiterated RatingBuy$129.00High
7/25/2018Bank of AmericaUpgradeNeutral ➝ Buy$135.00High
7/20/2018Jefferies Financial GroupReiterated RatingHold$119.00Low
7/19/2018Royal Bank of CanadaReiterated Rating$110.25$128.00Low
7/3/2018Raymond JamesUpgradeOutperform ➝ Strong-BuyMedium
6/18/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
4/13/2018The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
4/9/2018ArgusBoost Price TargetBuy ➝ Buy$110.00 ➝ $112.00Low
3/7/2018SunTrust BanksUpgradeHold ➝ BuyLow
2/15/2018Royal Bank of CanadaSet Price TargetBuy$118.00Low
2/15/2018Piper Jaffray CompaniesReiterated RatingHold$103.00Low
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight$115.00 ➝ $120.00Low
1/24/2018MizuhoSet Price TargetHold$97.00Low
1/22/2018SunTrust BanksReiterated RatingHold$110.00Low
1/18/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$112.00High
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$112.00Low
11/10/2017KeyCorpReiterated RatingOverweight ➝ Sector Weight$100.00N/A
11/9/2017Morgan StanleyBoost Price TargetOverweight$96.00 ➝ $121.00N/A
11/9/2017MizuhoDowngradeBuy ➝ Neutral$90.00N/A
11/3/2017SunTrust BanksReiterated RatingHold$114.00N/A
10/31/2017Credit Suisse GroupReiterated RatingOutperform$115.00 ➝ $125.00N/A
10/30/2017Jefferies Financial GroupBoost Price TargetHold$107.00 ➝ $110.00N/A
10/27/2017BarclaysBoost Price TargetOverweight$100.00 ➝ $120.00N/A
10/27/2017Stifel NicolausUpgradeHold ➝ Buy$92.00 ➝ $128.00N/A
10/16/2017Credit Suisse GroupReiterated RatingOutperform$98.00 ➝ $110.00N/A
10/9/2017Robert W. BairdReiterated RatingHold$98.00N/A
9/24/2017KeyCorpReiterated RatingBuy$100.00Low
9/19/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$116.00Low
9/18/2017ArgusBoost Price TargetBuy$98.00 ➝ $104.00Low
8/7/2017CitigroupBoost Price TargetNeutral$96.00 ➝ $97.00Low
8/4/2017Stifel NicolausReiterated RatingHold$87.00 ➝ $92.00Low
8/4/2017Jefferies Financial GroupReiterated RatingHold$94.00Low
8/4/2017BarclaysSet Price TargetBuy$98.00 ➝ $100.00Low
8/4/2017William BlairUpgradeMarket Perform ➝ Outperform$70.10 ➝ $93.42Low
7/17/2017BarclaysReiterated RatingOverweight$90.00 ➝ $98.00Low
7/7/2017Robert W. BairdUpgradeUnderperform ➝ Neutral$76.00 ➝ $93.00Medium
6/28/2017CitigroupReiterated RatingNeutral$87.00 ➝ $96.00Low
6/6/2017Credit Suisse GroupReiterated RatingOutperform$94.00 ➝ $96.00Low
5/15/2017Jefferies Financial GroupBoost Price TargetHold$78.00 ➝ $81.00Low
5/5/2017Jefferies Financial GroupReiterated RatingHold$78.00 ➝ $81.00Low
5/4/2017Evercore ISIReiterated RatingIn-Line$84.00 ➝ $88.50Low
5/4/2017MizuhoBoost Price TargetBuy ➝ Buy$90.00 ➝ $93.00Low
4/3/2017Jefferies Financial GroupReiterated RatingHold$78.00Low
3/31/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$89.00Low
2/17/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
2/15/2017Robert W. BairdDowngradeNeutral ➝ Underperform$80.00 ➝ $74.00N/A
2/3/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$81.00 ➝ $80.00N/A
12/16/2016The Goldman Sachs GroupDowngradeBuy ➝ Neutral$83.00N/A
12/13/2016MizuhoInitiated CoverageNeutral$90.00N/A
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 2 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/9/2021
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2021
  • 2 very positive mentions
  • 36 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2021
  • 9 very positive mentions
  • 41 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/8/2021

Current Sentiment

  • 9 very positive mentions
  • 41 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

IQVIA logo
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment provides mission critical information, technology solutions and real world solutions and services to the firm's life science clients. Research & Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment provides health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Read More

Today's Range

Now: $272.04
Low: $268.30
High: $272.84

50 Day Range

MA: $254.24
Low: $238.37
High: $270.30

52 Week Range

Now: $272.04
Low: $165.52
High: $272.25

Volume

26,376 shs

Average Volume

879,775 shs

Market Capitalization

$51.97 billion

P/E Ratio

69.05

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of IQVIA?

The following Wall Street analysts have issued reports on IQVIA in the last twelve months: Argus, Barclays PLC, Canaccord Genuity, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group Inc., KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Stephens, Stifel Nicolaus, Truist, Truist Securities, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for IQV.

What is the current price target for IQVIA?

18 Wall Street analysts have set twelve-month price targets for IQVIA in the last year. Their average twelve-month price target is $280.17, suggesting a possible upside of 3.7%. Citigroup Inc. has the highest price target set, predicting IQV will reach $320.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $230.00 for IQVIA in the next year.
View the latest price targets for IQV.

What is the current consensus analyst rating for IQVIA?

IQVIA currently has 1 hold rating and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IQV will outperform the market and that investors should add to their positions of IQVIA.
View the latest ratings for IQV.

What other companies compete with IQVIA?

How do I contact IQVIA's investor relations team?

IQVIA's physical mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company's listed phone number is (919) 998-2000 and its investor relations email address is [email protected] The official website for IQVIA is www.iqvia.com.